List of Excipients in Branded Drug NEVANAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	NEVANAC	nepafenac	0065-0002	BENZALKONIUM CHLORIDE	2027-01-31
Alcon Laboratories Inc	NEVANAC	nepafenac	0065-0002	CARBOMER HOMOPOLYMER TYPE B	2027-01-31
Alcon Laboratories Inc	NEVANAC	nepafenac	0065-0002	EDETATE DISODIUM	2027-01-31

NEVANAC Excipient Strategy and Commercial Opportunities in Nepafenac Ophthalmic Suspension

Last updated: August 21, 2026

NEVANAC is a preserved, topical ophthalmic suspension containing nepafenac 0.1%. Its commercial value depends less on active-ingredient differentiation than on suspension stability, ocular tolerability, microbial protection, sterile manufacturing, drop delivery, and generic substitution economics. The core excipient system is established and relatively accessible, creating opportunities for preservative-free reformulation, improved resuspendability, longer residence time, differentiated packaging, and lower-cost generic manufacturing.

What is NEVANAC and how is it positioned commercially?

NEVANAC contains nepafenac, a nonsteroidal anti-inflammatory drug used after cataract surgery to treat pain and inflammation. The labeled regimen is one drop three times daily, beginning one day before surgery and continuing on the day of surgery and for 14 days after surgery. The product is supplied as a 0.1% ophthalmic suspension in multidose bottles. [1]

Nepafenac is a prodrug converted in ocular tissues to amfenac, the pharmacologically active cyclooxygenase inhibitor. Because nepafenac is administered as a suspension rather than a solution, the formulation must maintain uniform drug distribution throughout the bottle and deliver a consistent dose after shaking. [1]

Attribute	NEVANAC profile
Active ingredient	Nepafenac
Strength	0.1% ophthalmic suspension
Route	Topical ophthalmic
Primary use	Post-cataract surgery pain and inflammation
Dosage form	Preserved multidose suspension
Administration	One drop three times daily
Original manufacturer	Alcon Laboratories
FDA pathway	New drug application
Generic pathway	Abbreviated new drug application
Biosimilar relevance	None; nepafenac is a small molecule
Primary formulation issue	Maintaining suspension uniformity and dose consistency

The product competes with other postoperative ophthalmic NSAIDs, including ketorolac, bromfenac and nepafenac 0.3% products such as ILEVRO. Pricing, formulary placement, surgeon preference, dosing frequency and generic availability determine commercial performance.

What excipients are used in NEVANAC?

The NEVANAC inactive-ingredient system includes mannitol, carbomer 974P, sodium chloride, benzalkonium chloride, edetate disodium, sodium hydroxide and/or hydrochloric acid for pH adjustment, and purified water. [1]

Excipient	Functional role	Commercial and technical relevance
Mannitol	Tonicity adjustment and formulation bulking	Helps achieve ocular tolerability and target osmolality
Carbomer 974P	Suspending and viscosity-enhancing polymer	Supports particle suspension and dose uniformity
Sodium chloride	Tonicity adjustment	Requires control because excessive ionic strength can affect polymer behavior
Benzalkonium chloride	Preservative	Enables multidose packaging but creates tolerability and chronic-use concerns
Edetate disodium	Chelating agent	Supports preservative performance and may bind trace metals
Sodium hydroxide and hydrochloric acid	pH adjustment	Used to control ocular comfort, chemical stability and preservative performance
Purified water	Vehicle	Must meet pharmaceutical and microbiological specifications

The excipients are conventional, but their combination is technically important. Carbomer concentration, nepafenac particle size, wetting behavior, mixing sequence, pH, ionic strength and filling conditions can materially affect redispersibility and delivered dose.

How does the NEVANAC suspension strategy work?

NEVANAC uses a low-strength polymeric suspension rather than a clear solution. This approach allows delivery of nepafenac at the target concentration while managing the active ingredient's aqueous solubility limitations.

The main formulation controls are:

1. Particle-size distribution of nepafenac.
2. Wetting and deagglomeration during manufacture.
3. Carbomer hydration and viscosity.
4. Suspension settling rate.
5. Resuspension after storage.
6. Drop-size consistency.
7. Chemical and physical stability.
8. Preservative effectiveness.
9. Ocular comfort after administration.

The formulation must remain pourable and capable of rapid redispersion. Excessive viscosity can reduce drop delivery, impair bottle usability and increase blurred vision. Insufficient viscosity can increase sedimentation and create dose variability between early and late doses.

The product label instructs patients to shake well before use. [1] That instruction is commercially relevant because generic products must deliver comparable performance under ordinary patient handling, not merely demonstrate chemical equivalence.

Why carbomer 974P matters

Carbomer 974P is a cross-linked polyacrylic acid polymer used to increase viscosity and maintain suspended particles. It can provide a more stable suspension at low concentration, but performance depends on neutralization, electrolyte content and shear history.

A generic manufacturer changing polymer grade, molecular-weight distribution or neutralization profile may produce a product with different:

• Sedimentation behavior.
• Redispersion time.
• Drop force.
• Surface retention.
• Visual appearance.
• Patient perception.
• Delivered-dose uniformity.

These properties create technical differentiation opportunities even when the active ingredient and listed excipients remain unchanged.

Why benzalkonium chloride matters

Benzalkonium chloride permits multidose use by limiting microbial growth after opening. Its presence also creates a recognized opportunity for reformulation because repeated exposure can contribute to ocular-surface irritation, epithelial effects and patient preference for preservative-free products.

NEVANAC is used primarily for a limited postoperative course, which reduces cumulative preservative exposure compared with chronic glaucoma therapy. Even so, cataract patients may receive several preserved ophthalmic products simultaneously, including antibiotics, corticosteroids and NSAIDs. A preservative-free nepafenac suspension could therefore support premium positioning, hospital formulary adoption and combination regimens focused on ocular-surface tolerability.

What formulation patents protect NEVANAC?

The original NEVANAC product was protected through patents covering nepafenac chemistry, ophthalmic formulations and therapeutic uses. Public patent records associated with nepafenac and Alcon products include U.S. patents in the 5-million and 6-million series, but patent relevance depends on the specific claims, terminal disclaimers, patent-term adjustments, pediatric extensions and Orange Book listing history.

The practical barrier today is unlikely to be a broad composition patent covering every nepafenac ophthalmic suspension. The more relevant risks are formulation-specific claims involving:

• Nepafenac particle size.
• Suspension stability.
• Polymer systems.
• Concentration ranges.
• Dosing schedules.
• Postoperative use.
• Diabetic macular-edema or cystoid-macular-edema risk reduction.
• Preservative and packaging combinations.

A claim-by-claim freedom-to-operate analysis is required before commercial development. Excipients themselves are generally difficult to protect as broad commercial barriers because mannitol, carbomer, sodium chloride, benzalkonium chloride and edetate disodium are established pharmaceutical materials. Patent value is more likely to arise from their specific combination, concentration, process conditions or performance characteristics.

When does NEVANAC lose exclusivity and what is the generic status?

NEVANAC's principal market protection has expired or has been substantially eroded by generic nepafenac ophthalmic suspension products. Generic development proceeds through the ANDA pathway because nepafenac is a small molecule and the reference product is approved as an ophthalmic suspension.

The key commercial distinction is between regulatory approval and the expiration of each patent claim. An ANDA may be approved with a Paragraph IV certification, a section viii carve-out for patented methods of use, or after relevant patents expire. The FDA Orange Book remains the controlling source for current listed patents and exclusivity. [2]

Exclusivity issue	NEVANAC implication
New chemical entity exclusivity	Historical period; expired
Five-year NCE exclusivity	No current barrier
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
ANDA pathway	Available for nepafenac ophthalmic suspension
Paragraph IV risk	Relevant to any unexpired listed patent
Section viii strategy	Possible for carved-out methods of use
Generic substitution	Commercially material where state substitution rules apply

Publicly available product information identifies generic nepafenac ophthalmic suspension products, confirming that the principal product-level barrier has been breached. [3] Current approval dates, patent certifications and marketing status must be evaluated against the live Orange Book and FDA Drugs@FDA records for transaction or litigation decisions.

What Paragraph IV challenges and litigation affect NEVANAC?

NEVANAC is exposed to the standard generic challenge model for an off-patent small-molecule ophthalmic product. A generic sponsor can challenge listed patents through Paragraph IV certification or omit protected indications through a section viii statement.

The most relevant litigation questions are:

• Whether any formulation patent remained listed when the ANDA was filed.
• Whether the generic product used a non-infringing polymer or preservative system.
• Whether method-of-use claims covered the proposed label.
• Whether a 30-month stay was triggered.
• Whether the brand and generic sponsor entered a launch settlement.
• Whether authorized-generic supply altered market entry economics.

No major continuing litigation or settlement should be assumed solely from the existence of historical NEVANAC patents. Litigation status must be checked in FDA records, federal court dockets and patent assignment databases. The principal current commercial risk is generic price erosion rather than a new Paragraph IV event.

What commercial opportunities exist in NEVANAC excipients?

Preservative-free nepafenac suspension

A preservative-free product could target patients with ocular-surface disease, high postoperative drop burden or documented sensitivity to benzalkonium chloride. The main challenge is packaging. Unit-dose containers, preservative-free multidose valves and sterile blow-fill-seal systems increase manufacturing and packaging cost.

The opportunity is strongest where hospitals, ambulatory surgery centers and ophthalmology groups value ocular-surface tolerability over the lowest acquisition price.

Improved suspension technology

A redesigned suspension could compete through:

• Faster redispersion.
• Lower sedimentation.
• More consistent dose delivery.
• Reduced shaking requirement.
• Smaller or more ergonomic bottle design.
• Lower residual volume.
• Improved drop-size control.

These claims may support product differentiation even if they do not create strong patent exclusivity.

Lower-viscosity delivery

Reducing viscosity while maintaining suspension stability could improve drop formation and reduce transient visual disturbance. The technical trade-off is greater settling and potential dose nonuniformity. This opportunity requires comparative testing under storage, transport and patient-use conditions.

Mucoadhesive or residence-enhancing systems

A mild residence-enhancing excipient system could reduce drainage and increase ocular contact time. Potential materials include carefully selected polymers or viscosity modifiers, but any change must preserve tolerability, sterility, redispersion and drop delivery. A more viscous product could also undermine patient acceptance.

Combination packaging

Cataract patients commonly receive multiple topical products. Commercial opportunities include co-packaging with an antibiotic or corticosteroid, synchronized dosing instructions, or an integrated postoperative kit. Combination products raise regulatory, manufacturing and liability issues but may improve adherence and channel economics.

Device-led differentiation

Bottle closure systems, one-handed operation, dose counters and tamper-evident packaging can create commercial value without changing the active ingredient. These features are particularly relevant for older cataract patients with limited dexterity or poor vision.

How strong is the NEVANAC patent estate?

The patent estate is commercially weaker than it was during branded exclusivity because the active ingredient is a small molecule, the dosage form is conventional and generic products have entered the market. The remaining defensibility is likely concentrated in narrow formulation and method-of-use claims.

Estate component	Relative strength
Nepafenac composition patents	Low after historical expiration
Broad ophthalmic formulation claims	Low to moderate
Specific suspension-process claims	Moderate if technically narrow
Preservative-free reformulation claims	Potentially moderate
Method-of-use claims	Indication- and label-dependent
Manufacturing know-how	Moderate; difficult to identify publicly
Packaging and delivery patents	Moderate where device-specific
Brand and clinical familiarity	Commercial, not patent-based

Manufacturing know-how may remain more valuable than expired composition patents. Critical know-how can include active-particle milling, wetting-agent selection, carbomer hydration, sterile filtration strategy, filling controls and stability specifications.

How does NEVANAC compare with competing ophthalmic NSAIDs?

Product class	Typical formulation	Dosing advantage	Generic pressure	Excipient opportunity
Nepafenac 0.1%	Suspension	Three times daily	High	Preservative-free and redispersion improvements
Nepafenac 0.3%	Suspension	Once daily	High to moderate	High-value dose-concentration and stability work
Bromfenac	Solution or suspension depending on product	Often once or twice daily	High	Comfort, preservative reduction and packaging
Ketorolac	Solution	Multiple daily dosing	Very high	Low-cost manufacturing and tolerability
Branded combination products	Solution or suspension	Simplified regimen	Product-specific	Co-packaging and adherence

NEVANAC's principal weakness is dosing frequency relative to once-daily products. Its main technical advantage is an established nepafenac delivery platform with recognized postoperative use. A new entrant would need either a material acquisition-cost advantage or a credible improvement in tolerability, adherence, handling or postoperative outcomes.

What generic launch scenarios exist?

Low-cost conventional generic

The most likely strategy is a conventional preserved suspension matching the reference product's strength, dosage form and excipient architecture. This approach minimizes development risk but creates rapid price competition.

Premium preservative-free generic

A preservative-free multidose or unit-dose product could command a premium in selected channels. Its success would depend on packaging cost, reimbursement, hospital purchasing and evidence of improved ocular-surface tolerability.

Once-daily reformulation

A higher-strength or redesigned nepafenac product could pursue reduced dosing frequency. This would require new clinical, pharmacokinetic or pharmacodynamic support and may encounter separate formulation and method-of-use patents.

Platform licensing

An excipient supplier with a validated ophthalmic suspension platform could license polymer, preservative-free packaging or manufacturing technology to generic and specialty-pharma companies. The most attractive counterparties would be ophthalmic manufacturers with established sterile filling capacity but limited suspension expertise.

What regulatory barriers apply to NEVANAC excipient changes?

An excipient change can alter the regulatory pathway even when the active ingredient remains unchanged. For an ANDA, the sponsor generally must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the proposed dosage form. Ophthalmic suspensions require close attention to:

• Particle-size distribution.
• Assay and content uniformity.
• Redispersibility.
• Rheology.
• Drop size and delivered volume.
• Sterility.
• Preservative effectiveness.
• Extractables and leachables.
• Container-closure integrity.
• In-use stability.
• Ocular irritation and tolerability where required.

The FDA's product-specific guidance and ANDA review standards determine the evidence package. [4] A new formulation that materially changes preservative status, concentration, viscosity or delivery device may be better positioned as a 505(b)(2) product than as a simple ANDA, depending on the proposed product and labeling.

What is the revenue exposure from generic entry?

Generic entry creates rapid erosion in branded ophthalmic revenue because postoperative NSAIDs are commonly reimbursed through competitive pharmacy and surgical-care channels. The revenue impact is determined by:

• Number of approved generics.
• Generic substitution rules.
• Payer formulary placement.
• Wholesaler inventory.
• Institutional purchasing.
• Authorized-generic strategy.
• Brand copay support.
• Use in diabetic cataract populations.
• Availability of competing bromfenac and ketorolac products.

For an excipient supplier, the addressable opportunity is more attractive than the branded product revenue pool may suggest. Multiple generic manufacturers may require qualified sources of carbomer, preservative systems, sterile packaging and formulation-development services. The opportunity is recurring but price-sensitive.

Key Takeaways

• NEVANAC is a nepafenac 0.1% preserved ophthalmic suspension.
• Its critical excipient functions are suspension control, tonicity adjustment, preservation, chelation and pH control.
• Carbomer 974P is central to suspension stability and dose uniformity.
• Benzalkonium chloride creates a clear opportunity for preservative-free reformulation.
• Broad active-ingredient protection is no longer the principal commercial barrier.
• Generic competition makes conventional copies low-margin products.
• Higher-value opportunities include preservative-free packaging, improved redispersion, device differentiation and reduced dosing frequency.
• Manufacturing know-how may be more defensible than legacy composition patents.
• Current Orange Book listings, Paragraph IV certifications and litigation status require live record verification before a transaction or launch decision.
• Nepafenac has no biosimilar issue because it is a small molecule.

FAQs

Can NEVANAC be reformulated without benzalkonium chloride?

Yes. A preservative-free version could use unit-dose packaging, a validated preservative-free multidose container or sterile blow-fill-seal packaging. The formulation would require new container-closure, sterility, in-use stability and dose-delivery validation.

Which excipient is most important for a generic NEVANAC suspension?

Carbomer 974P is the most formulation-critical listed excipient because it affects settling, redispersion, viscosity and dose uniformity. Its performance depends on grade, concentration, neutralization and ionic environment.

Is a nepafenac ophthalmic suspension eligible for biosimilar approval?

No. Nepafenac is a synthetic small molecule. A generic nepafenac ophthalmic suspension would ordinarily use the ANDA pathway, while a reformulated or repositioned product may require a 505(b)(2) application.

Can a generic manufacturer change NEVANAC's excipients?

Yes, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality, sterility, stability and labeling. A material change to preservative status, suspension behavior or packaging can increase development and regulatory requirements.

What is the strongest commercial opportunity around NEVANAC today?

The strongest opportunity is a differentiated preservative-free or device-enabled nepafenac suspension supported by reliable redispersion, consistent drop delivery and a credible ocular-surface tolerability proposition. A conventional preserved generic is more exposed to price competition.

References

1. U.S. Food and Drug Administration. (2023). NEVANAC (nepafenac ophthalmic suspension) 0.1% prescribing information. Alcon Laboratories, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development